Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques
Open Access
- 1 January 2016
- journal article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 3, 16079
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyriaJournal of Hepatology, 2016
- 474. Consequences of Infusion Time on Efficiency of Intravenous Delivery of Vector Genomes to the LiverMolecular Therapy, 2016
- Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia BNew England Journal of Medicine, 2014
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primatesMolecular Genetics and Metabolism, 2011
- Adeno-Associated Virus-Mediated Gene Transfer to Nonhuman Primate Liver Can Elicit Destructive Transgene-Specific T Cell ResponsesHuman Gene Therapy, 2009
- Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primatesBlood, 2006
- Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseNature Medicine, 2006
- Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia BGene Therapy, 2004
- Preexisting Immunity to Adenovirus in Rhesus Monkeys Fails To Prevent Vector-Induced ToxicityJournal of Virology, 2002